Immunogenicity, Boostability, and Sustainability of the Immune Response after Vaccination against Influenza A Virus (H1N1) 2009 in a Healthy Population

Elisabeth Huijkskens,1* John Rossen,1 Paul Mulder,2 Ruud van Beek,3 Hennie van Vugt,1 Johannes Verbakel,1 Guus Rimmelzwaan,3 Marion Koopmans,3,4 and Marcel Peeters1†

Laboratory of Medical Microbiology and Immunology, St. Elisabeth Hospital, Tilburg, Netherlands; Laboratory for Microbiology and Infection Control, Amphia Hospital, Breda, Netherlands; Department of Medical Microbiology, Erasmus Medical Center, Rotterdam, Netherlands; and National Institute of Public Health and the Environment, RIVM, Bilthoven, Netherlands

Received 21 March 2011/Returned for modification 19 May 2011/Accepted 19 July 2011

The emergence of a new influenza A virus (H1N1) variant in 2009 led to a worldwide vaccination program, which was prepared in a relatively short period of time. This study investigated the humoral immunity against this virus before and after vaccination with a 2009 influenza A virus (H1N1) monovalent MF59-adjuvanted vaccine, as well as the persistence of vaccine-induced antibodies. Our prospective longitudinal study included 498 health care workers (mean age, 43 years; median age, 44 years). Most (89%) had never or only occasionally received a seasonal influenza virus vaccine, and 11% were vaccinated annually (on average, for >10 years). Antibody titers were determined by a hemagglutination inhibition (HI) assay at baseline, 3 weeks after the first vaccination, and 5 weeks and 7 months after the second vaccination. Four hundred thirty-five persons received two doses of the 2009 vaccine. After the first dose, 79.5% developed a HI titer of >40. This percentage increased to 83.3% after the second dose. Persistent antibodies were found in 71.9% of the group that had not received annual vaccinations and in 43.8% of the group that had received annual vaccinations. The latter group tended to have lower HI titers (P = 0.09). With increasing age, HI titers decreased significantly, by 2.4% per year. A single dose of the 2009 vaccine was immunogenic in almost 80% of the study population, whereas an additional dose resulted in significantly increased titers only in persons over 50. Finally, a reduced HI antibody response against the 2009 vaccine was found in adults who had previously received seasonal influenza virus vaccination. More studies on the effect of yearly seasonal influenza virus vaccination on the immune response are warranted.

On 11 June 2009, the World Health Organization declared the first influenza pandemic in 41 years (32). It was caused by a triple-reassortant influenza A (H1N1) virus that contained genes from avian, human, and swine influenza viruses. The hemagglutinin (HA) of this virus was derived from viruses that had been circulating in swine since their initial introduction during the influenza A virus (H1N1) pandemic in 1918 (8). Due to this separation in host species, each with its own dynamics of influenza virus evolution, the viral HA was antigenically very distinct from that of the circulating seasonal influenza virus H1N1 strains (7). Up to 6 January 2011, a total of 2,193 patients had been hospitalized and 63 patients had died in the Netherlands, with a greater risk of complications found in the age group of 5 to 14 years (27). The age distribution showed the highest impact in relatively young persons, correlating with the presence of cross-reactive antibodies with the H1N1 pandemic strain in older people that were induced originally after infection against H1N1 viruses that circulated before 1957 (15, 20, 33).

The emergence of the new influenza A virus (H1N1) variant led to a worldwide vaccination program, which was prepared in a relatively short period of time. Vaccination is the most important preventive measure for reducing morbidity and mortality and may also influence virus transmission. In the Netherlands, clinics used the 2009 influenza A virus (H1N1) monovalent MF59-adjuvanted vaccine (Focetria; Novartis), an inactivated influenza virus vaccine containing the influenza virus A/California/7/2009 (H1N1)v-like strain (X-179A) and the adjuvant MF59. MF59, an oil-in-water emulsion, is an adjuvant developed to improve the performance of vaccines in general (2) and has been shown to improve immune response to seasonal influenza virus vaccines in adults as well as in children (24, 30).

The aim of this study was to measure the humoral immunity before and after vaccination with the 2009 influenza A virus (H1N1) monovalent MF59-adjuvanted vaccine and to examine the duration of the immune response.

MATERIALS AND METHODS

Study design. From November 2009 through June 2010, we conducted a prospective, longitudinal study at St. Elisabeth Hospital and TweeSteden Hospital, Tilburg, Netherlands. Health care workers of both hospitals (≥18 years; if pregnant, only after 13 weeks of pregnancy) were eligible for inclusion. We collected demographic characteristics, including age, sex, comorbidity (scored as asthma, chronic obstructive pulmonary disease [COPD], diabetes, hypo- and hypertyroidism, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, celiac disease, autoimmune sclerosis, anemia, sarcoidosis, prolatinoma, arthro-
sis, gout, nephropathy, and carcinoma), and influenza virus vaccination status, by means of a short questionnaire.

Blood samples were collected prior to the first vaccination against influenza A virus (H1N1) 2009, before the second vaccination (3 weeks later), before the vaccination with trivalent seasonal influenza virus vaccine (5 weeks after the second vaccination), and 7 months after the second vaccination against influenza A virus (H1N1) 2009. The trivalent seasonal influenza virus vaccine consisted of influenza A virus H1N1 (2007), influenza A virus H3N2 (2007), and influenza B (2008) virus.

A comparison was made between the group of participants who had never or occasionally received seasonal influenza virus vaccine and those who had been vaccinated with seasonal influenza virus vaccine each year. Occasionally, vaccinated was defined as having received seasonal influenza virus vaccination sporadically but not yearly in the past. The study was approved by the local medical ethics committee. Written informed consent was obtained from all participants in the study.

Serology. Virus-specific antibodies were measured by a hemagglutination inhibition (HI) assay, using egg-grown A/California/7/2009 A (H1N1) pandemic virus and fresh red blood cells (RBCs) of turkeys in Alsever’s solution (Biotrad Ing, Netherlands). Virus had been purified by centrifugation through a sucrose gradient and concentrated to create an influenza virus zonal pool preparation. Four hemagglutinating units were yielded with a virus antigen dilution of 1:16. Serum samples were heat inactivated at 56°C and treated overnight at 37°C with receptor-destroying enzyme (RDE, cholera filtrate; CosmosBiomedical Ltd., Derbyshire, United Kingdom). The serum-antigen mixture was incubated for 45 min at room temperature, and subsequently RBCs (1%) were added to each well of the microtiter plate. A negative and a positive control were used, as were serum controls for each specimen to detect nonspecific hemagglutination. Finally, plates were read promptly when the RBC control had completely settled.

The HI titer was the reciprocal of the highest dilution of serum that inhibited virus-induced hemagglutination. Titers below the detection limit of 10 were assigned a value of 0.5, and 1,280 was the endpoint titration and also the highest dilution tested.

Comparison of serological data from different laboratories is complicated by a lack of standardization. This is caused by the use of various influenza virus strains and different receptor-destroying enzymes (homemade or commercially bought) and also by differences in quality and nature of red blood cells (1). Therefore, there is a poor reproducibility of the HI assay between laboratories. To overcome this problem, red blood cells and receptor-destroying enzyme were bought commercially, and we used a candidate international standard for antibody titers to pandemic H1N1 virus to correct our data (22).

Statistical analysis. For immunogenicity analyses, the geometric mean antibody titers (GMT) at each time point were used. GMT were computed by taking the antilog and expressed as percent changes. Differences between the group who had HI titers of ≥40 (Table 2). These titers were more frequently observed in persons receiving annual seasonal influenza virus vaccination (6 of 54 [11.1%]) than in persons without a history of seasonal influenza virus vaccination (16 of 443 [3.6%]) (P = 0.023). After the first vaccination, 346 of the 435 persons who returned for a second vaccination (79.5%) produced an immune response. After the second vaccination, this increased to 83.3% (284 of the 341 persons who had a third serum sample taken).

Seven months after the second vaccination, 94 (68.6%) of

---

**RESULTS**

Initially, 498 persons were included, a serum blood sample was taken, and the first vaccination was given. Three weeks later, 435 persons also received the second vaccination. In addition, a third serum sample was taken from 341 persons 5 weeks after the second vaccination. At 7 months after the second vaccination, a fourth serum sample was collected from 137 persons. Of these, 32 persons (28 persons who had not received annual vaccinations and 4 persons who had received annual seasonal influenza virus vaccinations) received a trivalent seasonal influenza virus vaccine in January 2010. One person was excluded due to nonspecific reactions in the HI assay. The median age of the persons was 44 years (range, 19 to 66 years). 69% of them were female, and 11% had a history of annual vaccinations against seasonal influenza virus (>50% for more than 10 years) (Table 1).

**TABLE 1. Demographic characteristics of the persons who were never/occasionally vaccinated or regularly vaccinated**

| Characteristic | All persons (n = 498) | Persons not annually vaccinated with seasonal influenza virus vaccine (n = 445) | Persons annually vaccinated with seasonal influenza virus vaccine (n = 54) |
|---------------|----------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------------|
| Age (yr)      |                      |                                                                                  |                                                                     |
| Mean          | 43                   | 43                                                                               | 48                                                                  |
| Median        | 44                   | 44                                                                               | 49                                                                  |
| Range         | 19–66                | 19–63                                                                            | 19–66                                                               |
| No. (%) vaccinated: |                   |                                                                                  |                                                                     |
| Before 2000   | 32 (59.2)            |                                                                                  |                                                                     |
| From 2001–2004| 13 (24.1)            |                                                                                  |                                                                     |
| After 2005    | 9 (16.7)             |                                                                                  |                                                                     |
| No. (%) of gender |                  |                                                                                  |                                                                     |
| Male          | 155 (31.1)           | 131 (29.6)                                                                       | 24 (44.4)                                                          |
| Female        | 343 (68.9)           | 312 (70.4)                                                                       | 30 (55.6)                                                          |
| No. (%) with comorbidity |            |                                                                                  |                                                                     |
| None          | 457 (91.8)           | 416 (93.9)                                                                       | 40 (74.1)                                                          |
| COPD/asthma   | 9 (1.8)              | 4 (0.9)                                                                           | 5 (9.2)                                                            |
| Diabetes mellitus | 3 (0.6)            | 0 (0)                                                                            | 3 (5.6)                                                            |
| Thyroidism    | 6 (1.2)              | 6 (1.4)                                                                           | 0 (0)                                                              |
| Rheumatoid arthritis | 4 (0.8)          | 3 (0.7)                                                                           | 1 (1.9)                                                            |
| Other         | 19 (3.8)             | 14 (3.1)                                                                          | 5 (9.2)                                                            |
| Total with comorbidity | 41 (8.2)          | 27 (6.1)                                                                          | 14 (25.9)                                                          |

* For one of the patients, the status of the seasonal influenza virus vaccination was missing.
The 137 persons who gave a fourth serum sample had HI titers of \( \geq 40 \), but the difference between the groups had increased remarkably: in the group without a history of annual vaccination, 87 persons (71.9\%) had a titer of \( \geq 40 \), whereas in the group who had received annual vaccinations, only 7 of the 16 persons (43.8\%) had a titer of \( \geq 40 \) \((P = 0.041)\). The trivalent seasonal influenza virus vaccine, given to 32 of the 137 persons, had no influence on the reduction in HI titer of the pandemic H1N1 virus.

The estimated final model using linear mixed modeling showed a significant interaction between age and time post-vaccination \((P = 0.004)\) and a nearly significant effect of history of previous vaccination \((P = 0.098)\), which were therefore both included in the final model. No significant effects were found for the other interaction terms or for comorbidity, gender, and seasonal influenza virus vaccination in 2010; therefore, they were all eliminated. A history of previous vaccination with seasonal influenza virus vaccine resulted in a nearly significant 30.6\% lower titer \((95\% \text{ confidence interval } [95\% \text{ CI}], 55.0\% \text{ lower to } 7.1\% \text{ higher})\).

The significant age-by-time interaction caused the effect of age at baseline on titer to be modified by time after vaccination as follows. Per year of age increase at baseline, the corresponding estimated decrease in titer was 2.4\% \((95\% \text{ CI}, 3.4 \text{ to } 1.4; P < 0.00005)\) at 3 weeks (after the first vaccination), 1.4\% \((95\% \text{ CI}, 2.3 \text{ to } 0.4; P = 0.0041)\) at 5 weeks (after the second vaccination), and 2.6\% \((95\% \text{ CI}, 4.3 \text{ to } 1.0; P = 0.0020)\) at 7 months (after the second vaccination).

Alternatively, one may explain the age-by-time interaction as the effect of time on titer being modified by age. The estimated percent changes in titer between the first and second vaccinations and between the first vaccination and 7 months after the second vaccination are presented in Table 3 at 30, 40, 50, and 60 years of age at baseline. For example, between the first and second vaccinations there was a significant increase in titer of 15.1\% \((95\% \text{ CI}, 6.4 \text{ to } 24.5; P < 0.0005)\) at 50 years of age, whereas at 60 years of age this increase in titer was 28.0\% \((95\% \text{ CI}, 13.2 \text{ to } 44.8; P < 0.0005)\). Between the first vaccination and 7 months after the second vaccination, the age-by-time interaction was less pronounced, as a significant decrease in titer of about 25\% was seen at 40, 50, and 60 years of age.

**DISCUSSION**

This study demonstrates that a single dose of a monovalent MF59-adjuvanted influenza virus vaccine with influenza A virus (H1N1) 2009 produced an antibody response in 346 of 435 persons (79.5\%). In addition, it was shown that a second vaccination had little or no additional effect on the antibody titers in persons under 50 years of age. However, significant in-

### TABLE 2. Immunogenicity after the first and second doses of the monovalent MF59-adjuvanted influenza virus H1N1 (2009) vaccine, as measured by a hemagglutination inhibition assay

| Immunogenicity endpoint | Persons never or occasionally vaccinated with seasonal influenza virus vaccine | Persons always vaccinated with seasonal influenza virus vaccine | Total | \(P\) value |
|-------------------------|-------------------------------|-----------------------------|-------|-------------|
| **Baseline**            |                               |                             |       |             |
| No. of persons          | 443                           | 54                          | 498\(^b\) | 0.019       |
| Geometric mean titer    | 5.8                           | 7.2                         | 5.9   | 0.023       |
| No. (% of persons with HI titer of \(\geq 1:40\)) | 16 (3.6)                    | 6 (11.1)                    | 22 (4.4) |             |
| **3 wk after first dose** |                               |                             |       |             |
| No. of persons          | 383                           | 51                          | 435\(^b\) | 0.025       |
| Geometric mean titer (IQR)* | 70.9 (40–160)               | 47.0 (20–160)               | 67.1 (40–160) |             |
| No. (% of persons with HI titer of \(\geq 1:40\)) | 310 (80.9)                 | 36 (70.6)                   | 346 (79.5) | 0.095       |
| **5 wk after second dose** |                               |                             |       |             |
| No. of persons          | 297                           | 44                          | 341   | 0.049       |
| Geometric mean titer (IQR) | 74.2 (40–160)              | 53.1 (40–135)              | 71.1 (40–160) |             |
| No. (% of persons with HI titer of \(\geq 1:40\)) | 249 (83.8)                 | 35 (79.5)                   | 284 (83.3) | 0.52        |
| **7 mo after second dose** |                               |                             |       |             |
| No. of persons          | 121                           | 16                          | 137   | 0.081       |
| Geometric mean titer (IQR) | 55.1 (20–80)              | 30.8 (20–40)               | 51.5 (20–80) |             |
| No. (% of persons with HI titer of \(\geq 1:40\)) | 87 (71.9)                  | 7 (43.8)                    | 94 (68.6) | 0.041       |

* IQR, interquartile range.
\(^b\) For one of the patients, the status of the seasonal influenza virus vaccination was missing.

### TABLE 3. Estimated percent change in titers compared with titers found after the first vaccination, adjusted for seasonal influenza virus vaccination by using linear mixed modeling

| Time point tested | % change in titer | \(P\) value | 95\% CI | Lower | Upper |
|-------------------|-------------------|-------------|--------|-------|-------|
| **After second dose at age (yr):** |                       |             |        |       |       |
| 30                | -7.0              | 0.24        | -17.7  | 5.0   |
| 40                | 3.4               | 0.40        | -4.3   | 11.8  |
| 50                | 15.1              | <0.0005     | 6.4    | 24.5  |
| 60                | 28.0              | <0.0005     | 13.2   | 44.8  |
| **After 7 mo at age (yr):** |                       |             |        |       |       |
| 30                | -22.6             | 0.11        | -43.5  | 6.1   |
| 40                | -24.4             | 0.006       | -38.0  | -7.7  |
| 50                | -26.1             | 0.001       | -38.5  | -11.3 |
| 60                | -27.9             | 0.025       | -45.8  | -4.0  |
creases in the proportion of persons with protective level HI titers were observed in older persons following booster vaccination. Finally, a statistically significant correlation was observed between increasing age and more rapid decline in HI titer over time.

The response to the first dose of the pandemic influenza virus vaccine was sufficient to fulfill the European licensure criteria for immunogenicity of influenza virus vaccines, in line with results of previous studies (7). The advice to provide an additional second vaccine dose was a matter of debate in our country and elsewhere but was recommended based on the concern that risk groups might have a less favorable response to a single vaccine dose, as had been described for seasonal influenza virus vaccines (14, 18). Indeed, we found a clear age-specific effect in response to vaccination, despite the presence of a strong adjuvant.

We found that age at time of vaccination itself had a negative effect on the HI titer. In the literature, conflicting results of the effect of age on the immune response to influenza virus vaccine have been described (3, 12, 26). In a quantitative review, Goodwin et al. described that the antibody response in the elderly (>65 years) is considerably lower than that in younger adults (12). In contrast, Remarque et al. described that lower HI titers were not caused by age or aging of the immune system but probably by differences in priming histories and concomitant diseases (26).

Our data indicate that this may be the case, as responses were lower and persisted for shorter times in persons with a history of seasonal influenza virus vaccination prior to pandemic influenza virus vaccination. This effect has repeatedly been observed in clinical and animal studies on trivalent seasonal influenza virus vaccines (5, 21, 28, 29). The mechanism behind it remains to be discovered, but it is tempting to speculate about the observation of Bodewes et al., who found a T cell-mediated protective effect of natural influenza virus infection to subsequent infection with heterologous strains in ferrets (4). This heterosubtypic immunity supposedly is suppressed by regular vaccination, thus influencing the impact of a subsequent infection with an antigenically distinct influenza virus strain (5).

Studies during the pandemic remained inconclusive, but some suggested increased severity of pandemic influenza in persons with prior seasonal influenza virus exposures. Skowronski et al. reported an increased risk of medically attended influenza virus H1N1 (2009) illness after prior vaccination with trivalent seasonal influenza virus vaccine 2008–2009 (29), but these findings have never been corroborated by others. Obviously, an alternative explanation may be that such observations are confounded by the fact that vaccination is often limited to older persons and persons with comorbidities, who therefore possibly have impaired immune functions (6, 12).

In any case, in our study, the clear increase in proportion of persons over 50 years with an adequate response to vaccination following a booster vaccination showed that the decision to provide a 2-dose schedule was advantageous for this age group. Moreover, our data suggest that immune responses after vaccination need to be evaluated more carefully, taking vaccination history into account.

A limitation of our study was that vaccination of the health care workers in our hospitals commenced in week 46 of 2009, which coincided with the pandemic influenza peak in the Netherlands. However, in this study, we found baseline protective antibodies (HI titer of ≥40) in only 4.4% of the study population, compared with 4 to 31% found in other studies, which suggests that the majority of study participants had not encountered pandemic influenza before vaccination (13, 19, 25). In addition, if people were naturally infected during the study period, we expected those effects to be randomly spread over the groups.

Previous studies reported the presence of some level of cross-reactive antibodies in persons born before 1957. Such cross-reactive antibodies may be present in these persons because the H1N1 subtype viruses before 1957 were more similar to the H1N1 (2009) than the H1N1 viruses that reemerged in the 1970s. We detected no difference in preexisting baseline titers to the 2009 H1N1 strain between individuals born before or after 1957, and no stronger immunologic response in HI titer was seen in this group (15, 20). This might be due to the small number of persons born before 1957 in this study.

A larger proportion of persons who were vaccinated annually than those who were unvaccinated had preexisting antibodies to the 2009 H1N1 strain. This finding resembles those of other studies, and the most likely explanation is that seasonal influenza virus vaccination induced antibodies that cross-react with 2009 H1N1 virus to a certain extent (15, 34).

Contrary to other studies, we did not find a difference in antibody response between men and women. Data from clinical trials of seasonal influenza virus vaccines reveal pronounced differences between antibody responses in men and women. HI titers are consistently higher in women than men, suggesting that women may be better protected against influenza disease (16, 17). Although the mechanisms underlying sex-specific differences in immune development are poorly understood, women have higher absolute CD4+ lymphocyte count and production of TH1 cytokines after immunization, as well as more sustained responses to antigenic challenge (9–11, 31). The absence of this difference in antibody response between men and women may be due to the use of MF59 as an adjuvant in the vaccine, which is known to enhance the immune response (2, 23, 24, 30).

**Conclusions.** In conclusion, in our population the first vaccination with a monovalent MF59-adjuvanted influenza virus H1N1 (2009) vaccine resulted in a titer of ≥40 in 79.5% of the participants, and 71.9% of the participants had persisting antibodies (HI titers of ≥40) in only 4.4% of the study population, which coincided with the pandemic influenza peak in the Netherlands. However, in this study, we found baseline protective antibodies (HI titer of ≥40) in only 4.4% of the study population, compared with 4 to 31% found in other studies, which suggests that the majority of study participants had not encountered pandemic influenza before vaccination (13, 19, 25). In addition, if people were naturally infected during the study period, we expected those effects to be randomly spread over the groups.

There was a reduced HI antibody response, although not significant, in adults who annually received seasonal influenza virus vaccination compared with that in adults who never or occasionally received seasonal influenza virus vaccination, suggesting a possible unfavorable effect on immunogenicity for adults who annually received seasonal influenza virus vaccination. The mechanism underlying this negative effect of previous vaccination is unclear and remains to be elucidated.
ACKNOWLEDGMENTS

We thank the health care workers for their critical role in this study. Furthermore, we thank Jeanine van Erkel for her technical assistance.

REFERENCES

1. Alvarez, M. M., et al. 2010. Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method. PLoS One 5:e10176.
2. Ansaldi, F., et al. 2009. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine 27:3345–3348.
3. Beyer, W. E., A. M. Palache, M. Baljet, and N. Masurel. 1989. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 7:385–394.
4. Bodewes, R., et al. 2011. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterotypic immunity against influenza A/H5N1 virus infection in ferrets. J. Virol. 85:2695–2702.
5. Bodewes, R., J. H. Kreijtz, and G. F. Rimmelzwaan. 2009. Yearly influenza vaccinations: a double-edged sword? Lancet Infect. Dis. 9:784–788.
6. Centers for Disease Control and Prevention. 2010. Influenza vaccination: a summary for clinicians. http://www.cdc.gov/flu/professionals/vaccination/vax-summary.htm.
7. Clark, T. W., et al. 2009. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med. 361:2424–2435.
8. Cohen, J. 2010. Swine flu pandemic. What’s old is new: 1918 virus matches 2009 H1N1 strain. Science 327:1565–1564.
9. Cook, I. F. 2008. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 26:3551–3555.
10. Engler, R. J., et al. 2008. Half- vs full-dose trivalent inactivated influenza vaccine (2004–2005): age, dose, and sex effects on immune responses. Arch. Intern. Med. 168:2405–2414.
11. Ethaba, N., et al. 2011. Sex- and age-related differences in morbidity rates of 2009 pandemic influenza A H1N1 virus of swine origin in Japan. PLoS One 6:e19409.
12. Goodwin, K., C. Viboud, and L. Simonsen. 2006. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24:1159–1169.
13. Greenberg, M. E., et al. 2009. Response to a monovalent 2009 influenza A (H1N1) vaccine. N. Engl. J. Med. 361:2405–2413.
14. Gross, P. A., et al. 1987. Immunization of elderly people with two doses of influenza vaccine. J. Clin. Microbiol. 25:1763–1765.
15. Hancock, K., et al. 2009. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361:1945–1952.
16. Klein, S. L., A. Jellicka, and A. Pekosz. 2010. The X and Y of immune responses to viral vaccines. Lancet Infect. Dis. 10:338–349.
17. Klein, S. L., C. Passaretti, M. Anker, P. Olukoya, and A. Pekosz. 2010. The impact of sex, gender and pregnancy on 2009 H1N1 disease. Biol. Sex Differ. 1:5.
18. Levine, M., B. L. Beatie, and D. M. McLean. 1987. Comparison of one- and two-dose regimens of influenza vaccine for elderly men. CMAJ 137:722–726.
19. Madhun, A. S., et al. 2010. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 29:266–273.
20. Miller, E., et al. 2010. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 375:1100–1108.
21. Nabeshima, S., et al. 2007. Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years. J. Med. Virol. 79:320–325.
22. NIBSC. 2011. Influenza reagent WHO international standard for antibody to influenza H1N1 pdm virus. http://www.nibsc.ac.uk/documents/ifa/09-194.pdf.
23. Nicholson, K. G., et al. 2001. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357:1937–1943.
24. Pellegrini, M., U. Nicolay, K. Lindert, N. Groth, and G. Della Cioppa. 2009. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 27:6959–6965.
25. Plennevaux, E., E. Sheldon, M. Blatter, M. K. Reeves-Hoche, and M. Denis. 2010. Immune response after a single vaccination against 2009 influenza A H1N1 in U. S. A.: a preliminary report of two randomised controlled phase 2 trials. Lancet 375:41–48.
26. Remarque, E. J., I. A. de Bruijn, W. J. Boersma, N. Masurel, and G. J. Ligthart. 1998. Altered antibody response to influenza H1N1 vaccine in healthy elderly people as determined by HI, ELISA, and neutralization assay. J. Med. Virol. 58:8–87.
27. RIVM. 2011. Stand van zaken Nieuwe Influenza A (H1N1) in Nederland op 6 januari 2011. http://www.rivm.nl/elb/themas/griep/situatie-2010-2011/stand-van-zaken.jsp.
28. Roman, F., T. Vaman, F. Kafeja, E. Hanon, and P. Van Damme. 2010. AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin. Infect. Dis. 51:666–677.
29. Skowronska, D. M., et al. 2010. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: four observational studies from Canada. PLoS Med. 7:e1000258.
30. Vesikari, T., N. Groth, A. Karvonen, A. Borkowski, and M. Pellegrini. 2009. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 27:6291–6295.
31. Whitacre, C. C. 2001. Sex differences in autoimmune disease. Nat. Immunol. 2:777–780.
32. WHO. 2011. Pandemic (H1N1) 2009 in the European region. http://www.euro.who.int/influenza/ah1n1.
33. Xu, R., et al. 2010. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328:357–360.
34. Zimmer, S. M., and D. S. Burke. 2009. Historical perspective—emergence of influenza A (H1N1) viruses. N. Engl. J. Med. 361:279–285.